In this issue:
Stem cell support may bridge advanced patients to subsequent treatments
BCMA x CD3 bispecific antibody ABBV-383 has anti-myeloma activity
High response rates reported for first-in-class bispecific antibody talquetamab
Cilta-cel rapidly and durably improves health-related QoL
Patient perceptions regarding ciltacel treatment generally positive
MRD-negativity improved with isatuximab addition to front-line VRD
ELOQUENT-3: third- or later-line elotuzumab + Pd prolongs survival
Disparities in US haematological cancer clinical trial populations
Cobimetinib alone, and with venetoclax ± atezolizumab in RRMM
Elucidation of the mechanism of action of tasquinimod in myeloma
Please login below to download this issue (PDF)